A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ORAL, GUT-RESTRICTED ?4?7 INTEGRIN PEPTIDE ANTAGONIST PN-943 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE IDE
Walter Reinisch 1
1 Medical University of Vienna
Topic
IBD, Nurses, Primary Care
Conference
UEG Week Vienna 2022
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]
New to myUEG?
Social Sharing